Source comparison
ARA-290 Dosage for Inflammation: Practical Comparison
| Dose (mg) | Frequency | Duration | Target Inflammation Type | Biomarker Effect | Research Application | Professional Assessment ||—|—|—|—|—|—|| 2–3mg | Daily | 5–7 days | Mild acute inflammation (localized tissue injury) | IL-6 reduction 15–20%, minimal TNF-
This comparison does not assign a generated winner or score.
- | Dose (mg) | Frequency | Duration | Target Inflammation Type | Biomarker Effect | Research Application | Professional Assessment ||—|—|—|—|—|—|| 2–3mg | Daily | 5–7 days | Mild acute inflammation (localized tissue injury) | IL-6 reduction 15–20%, minimal TNF-α change | Exploratory dose-finding studies, mild inflammatory models | Suboptimal for most inflammatory endpoints. Receptor occupancy likely below saturation threshold || 4mg | Daily | 5–7 days | Moderate acute inflammation (post-surgical, traumatic injury) | IL-6 reduction 28–35%, TNF-α reduction 20–25% | Standard acute inflammation protocol, neuropathic pain models | Evidence-supported dose for acute inflammatory response; consistent biomarker changes across studies || 8mg | Daily | 5–7 days | Severe acute inflammation (sepsis models, ischemia-reperfusion) | IL-6 reduction 40–45%, TNF-α reduction 30–38% | High-intensity inflammatory models, systemic inflammation | Maximum effective dose before diminishing returns; receptor satu